Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential adebrelimab after chemotherapy for first-line extensive-stage small-cell lung cancer
ChiCTR2600131102Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Overall survival. Started Sep 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600131102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131102.